Abstract
Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Volume: 14 Issue: 1
Author(s): Sara Grammatico, Claudio Cartoni, Maria T. Petrucci, Pasquale Niscola, Marco Giovannini, Laura Scaramucci, Andrea Tendas, Adriana Costa, Marta Chisini, Gregorio A. Brunetti, Giada Mastrogiacomo, Sara Kiflom, Romina Talone, Giorgia Annechini, Ida Carmosino, Erminia Baldacci, Giacomo S. Morano and Giovanna Palumbo
Affiliation:
Keywords: Hematology, hematological malignancies, pain, stromal cells, syndromes, tapentadol.
Abstract: Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.
Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.
Methods: Our observational study included 36 patients with basal pain intensity (NRS) ranging from 5 to 10. Tapentadol prolonged release (PR) was given at the initial dose of 50 mg BID and careful titrated according to the achieved pain control. Results. Tapentadol PR was given at the dosages ranging from 200 and 260 mg/day after a careful titration, allowed for a clinically (-7 points NRS) remarkable reduction of pain intensity without any significant side effects.
Conclusion: In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.
Export Options
About this article
Cite this article as:
Grammatico Sara, Cartoni Claudio, T. Petrucci Maria, Niscola Pasquale, Giovannini Marco, Scaramucci Laura, Tendas Andrea, Costa Adriana, Chisini Marta, A. Brunetti Gregorio, Mastrogiacomo Giada, Kiflom Sara, Talone Romina, Annechini Giorgia, Carmosino Ida, Baldacci Erminia, S. Morano Giacomo and Palumbo Giovanna, Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2016; 14 (1) . https://dx.doi.org/10.2174/1871525714666160405110833
DOI https://dx.doi.org/10.2174/1871525714666160405110833 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer
Current Medicinal Chemistry Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot topic: Selected New Developments in Oncology (Guest Editors: Jos H. Beijnen and Jan H.M. Schellens)]
Current Clinical Pharmacology Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Current Cancer Therapy Reviews Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy
Current Drug Metabolism Lymphoblastoid Cell Lines Models of Drug Response: Successes and Lessons from this Pharmacogenomic Model
Current Molecular Medicine Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery.
Current Topics in Medicinal Chemistry Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews The Natural Tumor Suppressor Protein Maspin and Potential Application in Non Small Cell Lung Cancer
Current Pharmaceutical Design Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design